![Yale @ AWV-7785[57].jpg](https://images.squarespace-cdn.com/content/v1/66f1a668cb2280496659b3a0/f6e751ae-7da8-4189-8a99-08fc362f006f/Yale+%40+AWV-7785%5B57%5D.jpg)
Consortium Member of the Month
Our consortium members of the month for the month of August goes to Clinical Research Nurse Coordinators Amy T. Huan and Ann Gandhi from The University of Kansas Cancer Center!
Amy T. Haun, RN, CCRP
Ann Gandhi MSN, RN, CCRP
Amy and Ann, the dynamic duo study coordinators, often can be found at Dr. Yacoub’s clinic at the University of Kansas where they enroll patients for MPN-RC-106 . They enjoy being part of Dr. Yacoub’s team and MPN program, taking charge of prescreening all patients to clinical trials and ensuring every patients hears about the message of advocacy for research. Their thoroughness is unparalleled at capturing every study eligible subject, and every study encounter and procedure. Also, the KUMC Biospecimen Repository Core Facility contributes by processing and shipping labs, as well as entering data. Amy has made her fame by spreading the message that Biospecimen banking research is the way to patients can pay it forward.
Nominated by: Victoria A. Rivera
Amy and Ann, thank you so much for all of the phenomenal work you have done for the consortium.
Keep up the great work!
Title: Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era
Author(s): Ajay Major, Amylou C Dueck, Gita Thanarajasingam
MPN-RC Monthly Publication
MPN-RC Updates: ASH Conference 2024
-
![]()
ASH Conference 2024
(Left to Right: Susan Geyer, Carolyn Mead-Harvey, and Dr. Amylou Dueck) The Mayo Clinic group from the MPN Research Consortium attended the American Society of Hematology 2024 Conference in San Diego, California from December 7th - 10th.
-
![]()
ASH Conference 2024
Dr. Shivani Handa presents her ASH abstract “243 TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms”. View the abstract here!
-
![]()
ASH Conference 2024
Dr. Anna Rita Migliaccio asking after the talk at the plenary session on megakaryocytes in the elderly whether the GATA1low megakaryocytes which are enriched in the elderly represent an enrichment in the immune-megakaryocte subpopulations.
-
Bridget Kelly Marcellino, MD,PhD
873 Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells
-
Shivani Handa, MD
243 TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
